Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
Immunosuppressant
Small molecules
Tuberculosis
Crohn’s disease
Colon cancer
Inclusion
Maintenance therapy
MALT
MARKER
Dysbiose
Gènes
Contraindication
Eradication
Resistance
Microbiote
Helicobacter pylori
Algorithm
Ustekinumab
Disease Progression
PCR
Stricture
Ulcerative colitis
Clinical guidelines
Original Article Clinical
Disease progression
DNA METHYLATION
COLON-CANCER
Drug
RISK
IL12
Disability
Surgery
Bactéries
Methylation
HIV
Alkylating agents
Gene expression
Neoadjuvant chemotherapy
Upper gastrointestinal tract
Méthylation
Tailored therapy
IBD
Cost effectiveness
Clinical trial
Over 80s
Résistance
Patients experience
Biologics
IL23
Endoscopic treatment
Consensus
Venous thromboembolism
Colon
Survival
T1118 translocation
Effectiveness
Rituximab
Intestinal crypts
Inhibitor
Inflammatory bowel disease
Cancer
Primary sclerosing cholangitis
Inflammatory bowel diseases
Patient-reported outcome
Vedolizumab
Parvimonas micra
Heart disease risk factors
Epigenetics
Acceptability
Colorectal cancer Colibactin and lipids
Microbiota
MORTALITY
Colorectal cancer
Inflammatory Bowel Diseases
Safety
Gene methylation
Colectomy
CARCINOGENESIS
Thérapie ciblée
Crohn's disease
Eligibility
Dysbiosis
Cell adhesion
Bacteria
Monitoring
DNA methylation
MICROBIOTA
Rituximab plus chlorambucil
Kidney diseases
Colonic epithelial primary cells
Anti-TNF agents
Epigénétiques
Screening
Fecal microbiota
Immune cells
Anti-TNF
Genes
18 FDG-PET/CT
Therapeutics
Biomarker
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|